S100A1 and metabolic dysfunction-associated steatohepatitis: This should also allow the evaluation of the relevance of specific S100 members as new and robust biomarkers, and/or therapeutic targets, to add to the currently poor arsenal available for diagnostic/prognostic tools and chemotherapy for NAFLD/NASH and HCC, as well as for other inflammatory/fibrotic diseases and cancers.